Clinical Trial

Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC

Study acronym: METEORITE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-08-12; most recent amendment 2025-04-07.
Status change: Not Yet Recruiting → Recruiting 2025-04-07
Trial Details
NCT Number NCT06555133
Lead Sponsor Brown University
Collaborators: Sirtex Medical, Genentech, Inc.
Conditions Colorectal Carcinoma Metastatic in the Liver
Enrollment 18 participants
Start Date 2025-04-07
Primary Completion 2026-09-01 (estimated)
Study Completion 2029-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-09